278 related articles for article (PubMed ID: 23632889)
1. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
Ruan J; Luo M; Wang C; Fan L; Yang SN; Cardenas M; Geng H; Leonard JP; Melnick A; Cerchietti L; Hajjar KA
Blood; 2013 Jun; 121(26):5192-202. PubMed ID: 23632889
[TBL] [Abstract][Full Text] [Related]
2. Imatinib tackles lymphoma via the PDGFRβ+ pericyte.
Chute JP; Himburg HA
Blood; 2013 Jun; 121(26):5107-8. PubMed ID: 23813934
[No Abstract] [Full Text] [Related]
3. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
[TBL] [Abstract][Full Text] [Related]
4. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Lu C; Thaker PH; Lin YG; Spannuth W; Landen CN; Merritt WM; Jennings NB; Langley RR; Gershenson DM; Yancopoulos GD; Ellis LM; Jaffe RB; Coleman RL; Sood AK
Am J Obstet Gynecol; 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10. PubMed ID: 18395047
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
7. Expression of platelet-derived growth factor receptor β is maintained by Prox1 in lymphatic endothelial cells and is required for tumor lymphangiogenesis.
Miyazaki H; Yoshimatsu Y; Akatsu Y; Mishima K; Fukayama M; Watabe T; Miyazono K
Cancer Sci; 2014 Sep; 105(9):1116-23. PubMed ID: 24981766
[TBL] [Abstract][Full Text] [Related]
8. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression.
Tsioumpekou M; Cunha SI; Ma H; Åhgren A; Cedervall J; Olsson AK; Heldin CH; Lennartsson J
Theranostics; 2020; 10(3):1122-1135. PubMed ID: 31938055
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of platelet-derived growth factor receptor-β signaling mediated by integrin-associated MFG-E8.
Motegi S; Garfield S; Feng X; Sárdy M; Udey MC
Arterioscler Thromb Vasc Biol; 2011 Nov; 31(11):2653-64. PubMed ID: 21868707
[TBL] [Abstract][Full Text] [Related]
10. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis.
Hosaka K; Yang Y; Seki T; Nakamura M; Andersson P; Rouhi P; Yang X; Jensen L; Lim S; Feng N; Xue Y; Li X; Larsson O; Ohhashi T; Cao Y
Nat Commun; 2013; 4():2129. PubMed ID: 23831851
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
12. A differential role for CD248 (Endosialin) in PDGF-mediated skeletal muscle angiogenesis.
Naylor AJ; McGettrick HM; Maynard WD; May P; Barone F; Croft AP; Egginton S; Buckley CD
PLoS One; 2014; 9(9):e107146. PubMed ID: 25243742
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells.
Li L; Blumenthal DK; Masaki T; Terry CM; Cheung AK
J Cell Biochem; 2006 Dec; 99(6):1553-63. PubMed ID: 16817200
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological PDGFRβ inhibitors imatinib and sunitinib cause human brain pericyte death in vitro.
King NE; Courtney JM; Brown LS; Foster CG; Cashion JM; Attrill E; Premilovac D; Howells DW; Sutherland BA
Toxicol Appl Pharmacol; 2022 Jun; 444():116025. PubMed ID: 35443205
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β.
Ohishi J; Aoki M; Nabeshima K; Suzumiya J; Takeuchi T; Ogose A; Hakozaki M; Yamashita Y; Iwasaki H
BMC Cancer; 2013 May; 13():224. PubMed ID: 23642185
[TBL] [Abstract][Full Text] [Related]
16. Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth.
Thijssen VL; Paulis YW; Nowak-Sliwinska P; Deumelandt KL; Hosaka K; Soetekouw PM; Cimpean AM; Raica M; Pauwels P; van den Oord JJ; Tjan-Heijnen VC; Hendrix MJ; Heldin CH; Cao Y; Griffioen AW
J Pathol; 2018 Dec; 246(4):447-458. PubMed ID: 30101525
[TBL] [Abstract][Full Text] [Related]
17. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
Kim SJ; Uehara H; Yazici S; Busby JE; Nakamura T; He J; Maya M; Logothetis C; Mathew P; Wang X; Do KA; Fan D; Fidler IJ
J Natl Cancer Inst; 2006 Jun; 98(11):783-93. PubMed ID: 16757703
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma.
Zhang JB; Sun HC; Jia WD; Zhuang PY; Qian YB; Zhu XD; Kong LQ; Wang L; Wu WZ; Tang ZY
BMC Cancer; 2012 Oct; 12():439. PubMed ID: 23025904
[TBL] [Abstract][Full Text] [Related]
19. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Sennino B; Kuhnert F; Tabruyn SP; Mancuso MR; Hu-Lowe DD; Kuo CJ; McDonald DM
Cancer Res; 2009 May; 69(10):4527-36. PubMed ID: 19401451
[TBL] [Abstract][Full Text] [Related]
20. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats.
Schellings MW; Baumann M; van Leeuwen RE; Duisters RF; Janssen SH; Schroen B; Peutz-Kootstra CJ; Heymans S; Pinto YM
Hypertension; 2006 Mar; 47(3):467-74. PubMed ID: 16432052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
